Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621801 | 0.88 | MAPT (0.48) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL31619130 | 0.78 | AHR (0.42) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8623203 | 0.70 | ALDH1A1 (0.32) | CRBNMAPTALDH1A1CYP1A2TSHR | |
| SCHEMBL8620213 | 0.70 | ANPEP (0.32) | — | |
| SCHEMBL2438190 | 0.68 | PDE3B (0.39) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL7010445 | 0.68 | MAP2K1 (0.32) | CRBN | |
| SCHEMBL15828532 | 0.67 | — | — | |
| SCHEMBL4650183 | 0.64 | CRBN (0.40) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL31626731 | 0.64 | CYP11B1 (0.35) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24282441 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683554-B | Pyrrolopiperidone condensed ring derivative and synthetic method and application thereof | 重庆文理学院 | 2024-01-16 | — | — | CN | disclosed |
| CN-113683554-B | Pyrrolopiperidone condensed ring derivative and synthetic method and application thereof | 重庆文理学院 | 2024-01-16 | — | — | CN | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| EP-1432708-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027114-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO[3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | GPR119, GIPR, PGC | NPC1 2354/4885MAPK13 2867/4885MAPK12 2311/4885 |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | GPR119, GIPR, PGC | NPC1 2668/4885MAPK13 1858/4885MAPK12 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.